FIGO 2018年修订版分期系统中的一项重大变化是将IIIC期加入到之前使用的2009年系统中。我们评估了宫颈癌患者骨盆和/或主动脉旁淋巴结转移的预后价值。通过分析荷兰癌症登记数据库的数据，进行了一项全国性的回顾性队列研究。筛选出所有在2005年至2018年间新诊断为IB-IVA期的患者。使用Kaplan-Meier方法估计3年、5年和15年总体生存率（OS）。 在6082名患者中，1740名患者（29％）存在骨盆和/或主动脉旁淋巴结转移。对于FIGO 2009年期IB-IB1-IIA-IIA1以及期IB2-IIA2-IIB且存在骨盆和/或主动脉旁淋巴结转移的患者，其OS明显不同（p < 0.001和p = 0.009），5年存活率分别为77％和67％，而没有淋巴结转移的女性为92％和74％。对于存在和不存在淋巴结转移的FIGO 2009年IIIa- IIIB- IVA期，生存率没有明显差异（p = 0.064）。对于FIGO 2018年IIIC期，3年OS、5年OS和15年OS分别为72％、65％和59％。根据影像学检查诊断的IIICr患者的生存率明显较IIICp患者降低（p <0.001）。 FIGO 2009年期IB- IIB宫颈癌患者骨盆和/或主动脉旁淋巴结转移导致生存率明显降低，而FIGO 2009年IIIa-IVA期患者的生存率不受淋巴结转移的影响。版权所有©2023 Elsevier Inc. 发布。

One of the major changes in the revised (2018) FIGO-staging system is the addition of stage IIIC to the previously used 2009 system. We evaluated the prognostic value of positive pelvic and/or para-aortic lymph nodes in patients with cervical cancer.A nationwide retrospective cohort study was performed by analyzing data from the Netherlands Cancer Registry. All patients newly diagnosed with stage IB-IVA between 2005 and 2018 were identified. Three-year, 5-year and 15-year overall survival (OS) rates were estimated with the Kaplan-Meier method.Of the included 6082 patients, 1740 patients (29%) had pelvic and/or para-aortic lymph node metastases. For patients with FIGO 2009 stage IB-IB1-IIA-IIA1 and stage IB2-IIA2-IIB with pelvic and/or para-aortic lymph node metastases the OS was significantly different (p < 0.001 and p = 0.009), with a 5-year OS of 77% and 67%, compared with 92% and 74% for women without lymph node metastases. For FIGO 2009 stage IIIA-IIIB-IVA with and without lymph node metastases, survival rates are not significantly different (p = 0.064). For FIGO 2018 stage IIIC the 3y-OS, 5y-OS and 15-year OS are 72%, 65% and 59% respectively. Survival rates of IIIC diagnosed based on imaging (IIICr) are significantly impaired compared to stage IIIC diagnosed based on pathology (IIICp) (p < 0.001).Patients with FIGO 2009 stage IB-IIB cervical cancer with pelvic and/or para-aortic lymph node metastases have significantly impaired survival compared to patients without metastases. Survival rates of patients with FIGO 2009 stage IIIA-IVA are not affected by lymph node metastases.Copyright © 2023. Published by Elsevier Inc.